Dapagliflozin improves glycemic variability in subjects with type 2 diabetes mellitus when
added to insulin therapy. The primary objective of this study is to assess the effect of
dapagliflozin on glucose variability compared to placebo after 12 weeks of treatment in type
2 diabetic patients with inadequate glycemic control on insulin.
Phase:
Phase 4
Details
Lead Sponsor:
The Catholic University of Korea
Collaborators:
AstraZeneca Eulji General Hospital Kyung Hee University Hospital at Gangdong Severance Hospital